1. Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response
- Author
-
Oscar Bottasso, Silvina R. Villar, Laura Cordoba, Ana Rosa Pérez, Mariano Palatnik, Daniela Carbone, Rodolfo Leiva, Ignacio Rolla, Marcelo Abdala, Mariana Lagrutta, Juan Pablo Ruffino, Florencia Belén González, María Florencia Pacini, Maria Noel Cortese, María Florencia Martínez, Nadia Cuadranti, María Cecilia Argento, Damian Aguila, Ariana Ringer, and Serenela Chulibert
- Subjects
Chagas disease ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Trypanosoma cruzi ,chemical and pharmacologic phenomena ,Context (language use) ,Disease ,Gastroenterology ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Prednisone ,Internal medicine ,mental disorders ,medicine ,Humans ,Chagas Disease ,030212 general & internal medicine ,Prospective Studies ,030203 arthritis & rheumatology ,Immunosuppression Therapy ,business.industry ,Immunosuppression ,General Medicine ,medicine.disease ,Concomitant ,Rheumatoid arthritis ,Female ,business ,medicine.drug - Abstract
Evidence for Chagas disease reactivation (CDR) in rheumatologic patients under rheumatologic treatments (RTs) is scarce. To screen and follow-up patients with rheumatic diseases and concomitant Chagas disease under RT to detect CDR and to describe a possible relationship between CDR and specific RT. An observational, longitudinal, prospective, consecutive study was carried out between 2018 and 2020. Included patients were evaluated during the follow-up for clinical and laboratorial manifestations of CDR. Direct blood parasitological examination (Strout method) and polymerase chain reaction (PCR) were employed to diagnose CDR. The dynamic of anti-T. cruzi-specific antibodies was also assessed by IHA and ELISA (total IgG and Anti-SAPA). Fifty-one patients were included (86% women). Rheumatoid arthritis was the predominant disease (57%). Classic DMARDs (86.3%) and corticosteroids (61%) were the most frequent RT. CDR was developed in 6 patients (11.7%), exhibiting both positive Strout and PCR. Symptomatic reactivation of CD (fever, asthenia, arthralgias, myalgias) occurred in two patients who had previously been diagnosed with it. Regardless of the different RT, all patients who experienced CDR had previously received more than ≥ 20 mg/day of prednisone equivalent. Despite immunosuppression, patients with CDR exhibited increased levels of specific anti-T. cruzi and anti-SAPA antibodies, which decreased after anti-parasitic treatment. CDR is possible in rheumatologic patients, especially after receiving high doses of corticosteroids. Since CDR symptoms may mimic rheumatic disease activity, monitoring of Chagas disease is highly recommended before, during and after immunosuppression. Key Points • Chagas disease reactivation (CDR) in the context of rheumatological treatment was associated to high doses of corticosteroids. • CDR was associated with an increase in anti-T. cruzi antibodies despite the immunosuppressive treatment. • Suspecting and anticipating CDR is mandatory in this patient population to diagnose and treat it.
- Published
- 2020